Long-term Risk of Neoplasms After Childhood Growth Hormone Therapy in Patients with Turner Syndrome

Background Patients with Turner syndrome have a distinct pattern of neoplastic events occurrence, although their overall cancer risk does not appear to exceed that of the general population. Recombinant human growth hormone (rhGH) therapy is widely used to improve adult height, but concerns remain regarding its long-term safety. Objective To evaluate the long-term risk of neoplastic events among patients with Turner syndrome treated with rhGH during childhood and to examine associations between rhGH treatment duration or dose. Design, Setting and Participants Nationwide population-based cohort study including all Swedish patients with Turner syndrome treated with rhGH during childhood between 1983 and 2010 (n=583) and matched comparators (n=8745). Follow-up continued until the first neoplastic event, death, emigration or December 31, 2020. Results During a mean follow-up of 20.2 years (188445 person-years), patients with Turner syndrome had an increased hazard of overall neoplastic events (Hazard Ratio, HR, 2.0, 95% confidence interval, CI: 1.7-2.4), and of benign neoplasms (HR 2.5, 95% CI: 2.1-3.0), but not of malignant neoplasms (HR 0.7, 95% CI: 0.5-1.1). Hazards were increased for malignant neoplasms of the gastrointestinal tract and several benign neoplasms, while female genital malignancies were decreased. Neither rhGH treatment duration nor dose was associated with malignant or overall neoplastic risk. Conclusion and Relevance Patients with Turner syndrome treated with rhGH in childhood had an increased risk of overall neoplastic events driven primarily by benign neoplasms. No association was observed between rhGH treatment duration or dose and neoplastic risk in early to mid-adulthood, supporting its long-term safety.

Authors

Institutions

Publication Details

Journal
European Journal of Endocrinology
Published
2026-11-19
DOI
https://doi.org/10.1093/ejendo/lvag216
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term Risk of Neoplasms After Childhood Growth Hormone Therapy in Patients with Turner Syndrome

Karin Ekstrom Ekstroem Smedby, Tim R. J. Aeppli, Lars S Savendahl, Marie‐Louise Barrenäs et al.
European Journal of Endocrinology
Growth Hormone and Insulin-like Growth Factors
article

Long-term Risk of Neoplasms After Childhood Growth Hormone Therapy in Patients with Turner Syndrome

Karin Ekstrom Ekstroem Smedby, Tim R. J. Aeppli, Lars S Savendahl, Marie‐Louise Barrenäs, Matteo Bottai, Anders Tidblad
article en

Abstract

Background Patients with Turner syndrome have a distinct pattern of neoplastic events occurrence, although their overall cancer risk does not appear to exceed that of the general population. Recombinant human growth hormone (rhGH) therapy is widely used to improve adult height, but concerns remain regarding its long-term safety. Objective To evaluate the long-term risk of neoplastic events among patients with Turner syndrome treated with rhGH during childhood and to examine associations between rhGH treatment duration or dose. Design, Setting and Participants Nationwide population-based cohort study including all Swedish patients with Turner syndrome treated with rhGH during childhood between 1983 and 2010 (n=583) and matched comparators (n=8745). Follow-up continued until the first neoplastic event, death, emigration or December 31, 2020. Results During a mean follow-up of 20.2 years (188445 person-years), patients with Turner syndrome had an increased hazard of overall neoplastic events (Hazard Ratio, HR, 2.0, 95% confidence interval, CI: 1.7-2.4), and of benign neoplasms (HR 2.5, 95% CI: 2.1-3.0), but not of malignant neoplasms (HR 0.7, 95% CI: 0.5-1.1). Hazards were increased for malignant neoplasms of the gastrointestinal tract and several benign neoplasms, while female genital malignancies were decreased. Neither rhGH treatment duration nor dose was associated with malignant or overall neoplastic risk. Conclusion and Relevance Patients with Turner syndrome treated with rhGH in childhood had an increased risk of overall neoplastic events driven primarily by benign neoplasms. No association was observed between rhGH treatment duration or dose and neoplastic risk in early to mid-adulthood, supporting its long-term safety.

European Journal of Endocrinology
Karolinska University Hospital (SE), Karolinska Institutet (SE), Umeå University (SE)
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon